Back HIV Prevention

People with HIV and Uninfected People Diagnosed with Age-related Diseases at Similar Ages

HIV positive people are more likely than HIV negative individuals to have heart attacks and develop end-stage kidney disease and non-AIDS cancers in the era of effective antiretroviral therapy, but they do so at around the same ages, on average, according to study of U.S. veterans published in the October 30 edition of Clinical Infectious Diseases.

alt

Read more:

HIV R4P: RV144 HIV Vaccine's Effects Were Real -- and Could Be Made to Work Better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P) in Cape Town. They showed evidence of stronger antibody responses, and in-depth analysis of these responses suggests that by further developing a similar vaccine, it may be possible to push the immune system to generate an antibody response to HIV that is sufficiently strong to prevent most infections.

alt

Read more:

HIV Drug Therapy: Efavirenz Compromises Hormonal Contraceptive Implant

The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from a study conducted in Uganda presented this week at the HIV Drug Therapy Glasgow conference.

alt

Read more:

Complete Coverage of HIV Drug Therapy 2014

HIVandHepatitis.com coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.

Full listing of coverage by topic

HIV Drug Therapy 2014 website

11/4/14

alt

HIV R4P: Vaginal Rings Show Promise for HIV Prevention

A silicone intravaginal ring that releases the antiretroviral drugs dapivirine and darunavir was shown to reach levels expected to be effective in vaginal and cervical fluid and tissues in monkeys, researchers reported at the HIV Research for Prevention meeting last week in Cape Town. A related study found that a single ring can potentially serve multiple purposes, preventing HIV, genital herpes, HPV, and pregnancy.

alt

Read more:

HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks

Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.

alt

Read more:

HIV R4P: Injectable Rilpivirine Shows Promise, May Work Better for Anal than Vaginal Sex

A Phase 1 dose-finding and safety study in humans of TMC278-LA, a long-acting, injectable formation of the antiretroviral drug rilpivirine, found that a single 1200 mg dose could produce sustained drug levels in rectal tissues that could offer protection against HIV for 3 months, and did in fact suppress viral replication in so-called explants (biopsies of rectal mucosal cells) for that length of time. However -- and to the surprise of researchers presenting this study at the HIV Research for Prevention conference last week in Cape Town -- drug levels in vaginal and cervical cells were only about half of those seen in rectal cells, and viral replication was not suppressed in vaginal and cervical biopsies taken from women given TMC278-LA.

alt

Read more:

HIV R4P: The Immunity Project -- An Open-Access T-Cell Vaccine for HIV Infection

Microparticles containing conserved HIV epitopes may be able to prime antigen-presenting dendritic cells, which in turn activate antigen-specific CD8 killer T-cells, offering a potential new approach for developing T-cell-based preventive or therapeutic HIV vaccines, researchers with the open-access Immunity Project reported at the HIV Research for Prevention (HIV R4P) conference last week in Cape Town.

alt

Read more:

Coverage of HIV Research for Prevention Conference (HIV R4P)

HIVandHepatitis.com coverage of the HIV Research for Prevention Conference, October 28-31, in Cape Town.

This conference -- combining the previous HIV Vaccines and Microbicides meetings -- includes all aspects of HIV prevention including experimental vaccines, microbicide gels and rings, and pre-exposure prophylaxis (PrEP).

Full listing of coverage by topic

HIV R4P website

11/4/14

alt

HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART

Monotherapy with ritonavir-boosted darunavir (Prezista) results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), but may be just as effective as 3-drug therapy in people with nadir (lowest-ever) CD4 cell counts above 200 cells/mm3, according to a 48-week analysis of the PROTEA study presented last week at the HIV Drug Therapy Glasgow conference.

alt

Read more:

HIV R4P: Research for Prevention Conference Opens with Real Hope for HIV Vaccine

"There’s only one Berlin Patient still. But by this time next year he will at least be joined by 40-50 Portland monkeys." These were the words of vaccine researcher Louis Picker, summarizing in quotable form why the outlook for the development of an effective HIV vaccine is brighter than it has been for years, in a satellite session in advance of the HIV Research for Prevention conference (R4P) in Cape Town, South Africa.

alt

Read more:

HIV Drug Therapy: Doravirine Works as Well as Efavirenz with Fewer CNS Side Effects

Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side effects, researchers reported this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

alt

Read more:

HIV R4P: Injectable Cabotegravir Makes Progress, Doubts About Injectable Rilpivirine

Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK1256744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis (PrEP). Progress on an injectable formulation of another drug, rilpivirine, received a setback, however, when animal studies showed it lost its efficacy against viral challenge after only 18-21 days, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

alt

Read more:

Gilead Submits Request for FDA Approval of Tenofovir Alafenamide Coformulation

Gilead Sciences this week announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-tablet regimen containing tenofovir alafenamide (TAF) -- a new version of the widely used antiretroviral that causes less kidney and bone toxicity -- coformulated with its new integrase inhibitor elvitegravir, cobicistat, and emtricitabine.

alt

Read more:

HIV R4P: Tenofovir Gel Associated with Lower Herpes Simplex Risk for Women

The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% among women who regularly used a vaginal gel containing tenofovir, according to a secondary analysis of the VOICE trial presented at the HIV Research for Prevention conference (R4P) this week in Cape Town. There was no significant difference in the age, marital status, country, practice of anal sex, HIV status, or hormonal contraceptive use between women who acquired HSV-2 and those who did not.

alt

Read more:

HIV Drug Therapy: Truvada PrEP Use Rising, Especially Among Men

The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the U.S. is increasing, and a growing proportion of users are men, according to an analysis of data from approximately half of American pharmacies presented this week at the HIV Drug Therapy 2014 conference in Glasgow.

alt

Read more:

HIV R4P: Model Suggests More Frequent Truvada PrEP Needed for Vaginal vs Anal Sex

Tenofovir reaches lower levels in vaginal and cervical tissue compared with rectal tissue, helping to explain why pre-exposure prophylaxis (PrEP) did not protect women as much as gay and bisexual men in clinical trials, and suggesting that women having vaginal sex may need to take PrEP more often than people having anal sex, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

alt

Read more:

HIV Drug Therapy: Australia Performs Best in HIV Treatment Cascade -- 62% Undetectable Viral Load

Australia and northern European countries are doing far better than North America at retaining people living with HIV in care and achieving viral suppression, according to a comprehensive survey of treatment cascades in high-income countries presented this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

alt

Read more:

Second European PrEP Study Closed Early Due to High Effectiveness

In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomized phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. All participants assigned to receive placebo in the IPERGAY trial will be offered intermittent Truvada PrEP.

alt

Read more:

HIV Drug Therapy: Do Emtricitabine and Lamivudine Have Similar Efficacy for First-line ART?

First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the October 1 online edition of Clinical Infectious Diseases and at the HIV Drug Therapy Glasgow conference taking place this week. Lamivudine was associated a significantly increased risk of virological failure when used in these regimens.

alt

Read more:

HIV Research for Prevention Conference Features Advances in Vaccines, Microbicides, PrEP

The first HIV Research for Prevention -- or HIV R4P -- conference takes place this week in Cape Town, bringing together more than 1300 leading researchers, policymakers, and advocates working on interventions such as HIV vaccines, microbicides, antiretroviral treatment as prevention (TasP), and new forms of pre-exposure prophylaxis (PrEP). The conference incorporates the previously separate HIV vaccine and microbicide meetings as biomedical prevention technologies have converged.

alt

Read more: